COPD (chronic obstructive pulmonary disease) market booms but not without casualties:
This article was originally published in Clinica
The US chronic obstructive pulmonary disease (COPD) market is expected to grow from $1.89bn in 2001 to $2.97bn by 2008. However, inhaler manufacturers may not be among those to share in the booming market, as COPD drug manufacturers are increasingly opting for combination bronchodilators, says a new report by Frost & Sullivan. This will induce a shrinkage of the number of inhalers required to deliver multiple active ingredients, says the report, US Chronic Obstructive Pulmonary Disease Therapies.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.